Your Good Partner in Biology Research

CCR8

CCR8:Tregs細胞的特異性靶點,催生下一代重磅腫瘤免疫藥物!

CCR8在腫瘤浸潤的調節(jié)性T細胞(Treg)上特異性表達,在輔助型T細胞2(Th2)和腫瘤細胞也均有表達;然而在外周血Treg或正常組織上基本不表達。CCR8的主要作用是參與Tregs和Th2細胞向炎癥和腫瘤部位的募集。Tregs增強了腫瘤細胞的浸潤能力,通過抑制攻擊腫瘤的免疫細胞的免疫反應,從而使腫瘤細胞發(fā)生免疫逃逸。研究發(fā)現(xiàn),與正常組織中的Tregs相比,CCR8在人類乳腺癌的腫瘤浸潤性Tregs中顯著上調,表明CCR8是TME中Tregs上的一個有希望的治療靶點,而不會引起系統(tǒng)性自身免疫。因此,以CCR8為靶點的抗體,清除腫瘤微環(huán)境中的Treg細胞,將改善TME的免疫功能。

CUSABIO-哺乳包膜VLPs平臺成功開發(fā)CCR8全長膜蛋白(7次跨膜),展示了完整生物活性。

Recombinant Human CCR8-VLPs 活性蛋白實驗驗證數(shù)據(jù)

● 經WB驗證蛋白特異性

CSB-MP004847HU is detected by Mouse anti-6*His monoclonal antibody.

CSB-MP004847HU is detected by Anti-CCR8 recombinant Antibody

● 功能性ELISA驗證高活性

Immobilized human CCR8 at 5 μg/ml can bind Anti-CCR8 recombinant Antibody. The EC50 is 11.13-17.29 ng/mL.

● 經TEM驗證蛋白正確組裝

The VLP-like structures of CCR8 has been confirmed by TEM.

CCR8 Antibodies

CCR8 for Homo sapiens (Human)

CCR8 Proteins

CCR8 Proteins for Homo sapiens (Human)

CCR8 Proteins for Mus musculus (Mouse)

CCR8 Proteins for Macaca mulatta (Rhesus macaque)